Photoinduced Conversion of Antimelanoma Agent Dabrafenib to a Novel Fluorescent BRAF(V600E) Inhibitor

[Image: see text] Dabrafenib (Tafinlar) was approved in 2013 by the FDA as a selective single agent treatment for patients with BRAF(V600E) mutation-positive advanced melanoma. One year later, a combination of dabrafenib and trametinib was used for treatment of BRAF(V600E/K) mutant metastatic melano...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinchuk, Boris, von Drathen, Thorsten, Opel, Viktoria, Peifer, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066145/
https://www.ncbi.nlm.nih.gov/pubmed/27774137
http://dx.doi.org/10.1021/acsmedchemlett.6b00340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066145/
https://www.ncbi.nlm.nih.gov/pubmed/27774137
http://dx.doi.org/10.1021/acsmedchemlett.6b00340

Ejemplares similares